Comparative study of hypoglycaemic and antioxidant potential of methanolic seed extract and oil of Nigella sativa on alloxanized diabetic rabbits.

The present study was aimed to investigate the comparative antidiabetic potential of Nigella sativa seed extract and oil in an in vivo trial using rat animal model. The levels of antioxidants analysed in this study included catalase, vitamin C and bilirubin. NS methanolic extract and its oil were tested for their hypoglycemic effect against alloxanized diabetic rabbits (120mg/kg). The crude methanolic extract and the oil (2.5ml/kg/day) were given orally for 24 days that resulted in a significant reduction in glycaemia, particularly during the first 12 days of treatment (reductions of 58.09% and 73.27%, respectively), whereas the oil treated group normalised the levels of catalase (-69.23%), vitamin C (27.30%) and bilirubin (-51.48%) and the extract treated group normalised the levels of catalase (-65.38), vitamin C (24.15%) and bilirubin (-26.19%) at the end of the trial. The results have shown that the seed oil more significantly normalized the levels of serum catalase, serum ascorbic acid and total serum bilirubin as compared to the methanolic extract of Nigella sativa, so Nigella sativa seed oil (NSO) may be used as part of antidiabetic remedies against diabetes and utilized as a nutraceutical.

Antioxidant, Hypoglycemic, Antilipidemic, and Protective Effect of Polyherbal Emulsion (F6-SMONSECCE) on Alloxan-Induced Diabetic Rats.

The current study focused on the antioxidant potential, α-amylase inhibitory activity, and hypoglycemic, hypolipidemic, and histoprotective (pancreas and kidney) effects of polyherbal emulsion on the alloxan-induced diabetic rats. Polyherbal formulations were prepared from extracts and oils of Nigella sativa (N. sativa), Citrullus colocynthis (C. colocynthis), and Silybum marianum (S. marianum). Out of nine stable formulations, one formulation named F6-SMONSECCE was found to be the best after its evaluation using antioxidant and in vitro α-amylase inhibition assay. The prepared herbal formulations showed significant (p < 0.05) antioxidant activity in terms of radical scavenging as 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric-reducing antioxidant power (FRAP) assays and also revealed the presence of a significant amount of total phenolic and flavonoid contents. "F6- SMONSECCE" (prepared with composition; Silybum marianum oil (SMO) + Nigella sativa extract (NSE) + Citrullus colocynthis extract CCE) was selected for an in vivo trial to ascertain its antidiabetic potential. The treatment dose was determined by using an acute toxicity trial on rats. Administration of alloxan (150 mg/kg b.w., i.p.) significantly (P < 0.05) augmented the blood glucose levels and lipid contents as total cholesterol (TC), triglycerides (TG), low-density lipoproteins (LDL-c), and very-low-density lipoproteins (VLDL-c). However, the levels of insulin and high-density lipoproteins (HDL-c) were found to be decreased, and the histopathological alterations were also found in the pancreas and kidney. The administration of the polyherbal formulation (F6-SMONSECCE) significantly attenuated the blood glucose levels (22.94%), TC (29.10%), TG (38.15%), LDL-c (27.58%), and VLDL-c (71.52%), whereas on the other side, the insulin (-149.15%) and HDL-c levels (-22.22%) were significantly increased. A significant histopathological normalization was observed in the pancreas and kidney tissues of the F6-SMONSECCE-treated rats. The current findings proposed that the prepared polyherbal formulation "F6-SMONSECCE" exhibited significant antioxidant, antilipidemic, and hypoglycemic potential and hence might be suggested as a remedy against diabetes or as a coadjuvant to synthetic medicines to maintain normal physiology.